Literature DB >> 29132563

When Does Atypical Ductal Hyperplasia Require Surgical Excision?

Jennifer M Racz1, Amy C Degnim2.   

Abstract

Atypical ductal hyperplasia (ADH) is a proliferative, nonobligate precursor breast lesion and a marker of increased risk for breast carcinoma. Surgical excision remains the standard recommendation following a core needle biopsy result consistent with ADH. Recent research suggests that women with no mass lesion or discordance, removal of greater than or equal to 90% of calcifications at the time of core needle biopsy, involvement of less than or equal to 2 terminal duct lobular units, and absence of cytologic atypia or necrosis are likely to have a less than 5% chance of a missed cancer.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical ductal hyperplasia; Core needle biopsy; Epithelial proliferative lesion; Surgical excision

Mesh:

Year:  2018        PMID: 29132563     DOI: 10.1016/j.soc.2017.07.011

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN: 1055-3207            Impact factor:   3.495


  3 in total

1.  Breast lesions with atypia in percutaneous biopsies, managed with surgery in the last 10 years.

Authors:  Mitzy Carrillo; Gregorio Maturana; Cristóbal Maiz; Diego Romero; Francisco Domínguez; David Oddó; Alejandra Villarroel; Dravna Razmilic; María Elena Navarro; Augusto León; César Sánchez; Mauricio Camus
Journal:  Ecancermedicalscience       Date:  2019-04-11

2.  Detection rate of breast malignancy of needle localization biopsy of breast microcalcification.

Authors:  Kian-Hwee Chong; Kuo-Feng Huang; Hsiu-Wen Kuo; I-Shiang Tzeng; Jia-Hui Chen
Journal:  Tzu Chi Med J       Date:  2021-03-22

3.  Atypical ductal hyperplasia and the risk of underestimation: tissue sampling method, multifocality, and associated calcification significantly influence the diagnostic upgrade rate based on subsequent surgical specimens.

Authors:  Christoph J Rageth; Ravit Rubenov; Cristian Bronz; Daniel Dietrich; Christoph Tausch; Ann-Katrin Rodewald; Zsuzsanna Varga
Journal:  Breast Cancer       Date:  2018-12-27       Impact factor: 4.239

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.